Immunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $80.92.

A number of analysts have issued reports on IMCR shares. Canaccord Genuity Group boosted their price target on shares of Immunocore from $60.00 to $63.00 and gave the stock a “hold” rating in a research note on Thursday, February 29th. Needham & Company LLC reiterated a “buy” rating and set a $81.00 price target on shares of Immunocore in a research note on Thursday, April 11th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Immunocore in a research note on Wednesday, March 6th. SVB Leerink started coverage on shares of Immunocore in a research note on Monday. They set an “outperform” rating and a $74.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th.

Immunocore Trading Down 0.6 %

NASDAQ IMCR opened at $58.10 on Tuesday. The firm’s 50-day moving average is $62.10 and its two-hundred day moving average is $60.89. Immunocore has a 12 month low of $42.21 and a 12 month high of $76.98. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.80 and a quick ratio of 3.77. The stock has a market capitalization of $2.89 billion, a P/E ratio of -50.09 and a beta of 0.89.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.12). Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The company had revenue of $70.16 million during the quarter, compared to analyst estimates of $53.25 million. During the same period in the previous year, the company earned ($0.63) EPS. The company’s quarterly revenue was up 22.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Immunocore will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its holdings in Immunocore by 7.0% in the first quarter. Principal Financial Group Inc. now owns 517,204 shares of the company’s stock valued at $33,618,000 after purchasing an additional 33,868 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Immunocore by 69.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after purchasing an additional 2,721 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Immunocore by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company’s stock valued at $5,695,000 after purchasing an additional 1,830 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in Immunocore by 71.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 21,232 shares of the company’s stock valued at $1,380,000 after purchasing an additional 8,848 shares in the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Immunocore by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after purchasing an additional 399,201 shares in the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.